

IN THE CLAIMS:

Amend the claims as follows.

1. (Original) A peptide having, in particular, an antiangiogenic activity, characterized in that it is a cyclized peptide corresponding to the sequence

SEQ ID No 1: $X_1X_2RGDX_3FGX_4X_5LLFIHFX_6IGSX_7HSX_8IX_9$ in which:

- the letters without any numerical index correspond to amino acids defined by the single-letter international code,
- X_1 is either a G or a GG, the amino-terminal end of which is free, alkylated, acylated, or in particular acetylated, or contains a labeling group, such as the biotinyl group,
- X_2 is either a C, in which case $X_2 = X_4$, the two Cs then being connected by a disulfide bridge, or X_2 is capable of forming a lactam bridge with X_4 , one of X_2 or X_4 being an amino acid bearing an acid group, such as A or D, the other bearing an amino function, such as Q or N,
- X_3 is either an M motif or a norleucine motif,
- X_5 is either a motif, or a succession of two di-, tri- or tetrapeptide motifs composed of G or a combination of G and of S, such as GG, GGG, GGGG, GGS, GGGG or GGSGGS, or else X_5 is a C motif, the side chain (thiol function) of which serves as a point for covalent bonding with a 3-nitro-2-pyridinesulfonyl group located on the N-terminal end of the next amino acid (L),

- X_6 is either an R motif or a K motif,
- X_7 is either an R motif or a K motif,
- X_8 is either an R motif or a K motif,
- X_9 is an aliphatic amino acid (such as G or A), the C-terminal end of which is amidated.

2. (Original) The peptide as claimed in claim 1, characterized in that it corresponds to the sequence

SEQ ID No 2: GG*CRGDMFG*CGLLFIHFRIGSRHSRIG (*indicates a disulfide bridge connecting the two C motifs).

3. (Currently Amended) The peptide as claimed in claim 1 [[or 2]], characterized in that it is modified compared with the native peptide and has, in particular, an alkylated group at its N-terminal end, and/or in that more amino acids are replaced with one or its/their dextrorotary form (D_{aa}), and/or in that it contains one or more peptide bonds so as to form bioisosters, for example the reduction of an amide bridge to $-CH_2NH-$, or a retro-inverso reaction.

4. (Original) The peptide as claimed in claim 2, in which the RGD motif is exposed via a disulfide bridge between two cysteines, in particular the peptides of sequences SEQ ID No 3 to 10:

SEQ ID No 3: GG*CRGDMFG*CGLLRIHFRIGSRHSRIG

SEQ ID No 4: GG*CRGDMFG*CGG-LFIHFRIGSRHSRIG

SEQ ID No 5: GG*CRGDMFG*CGGSLFIHFRIGSRHSRIG

SEQ ID No 6: GG*CRGDMFG*CGGLLFIHFKIGSRHSRIG

SEQ ID No 7: GG*CRGDMFG*CGGLLFIHF^NRIGSRHSRIG

(^NR representing an N-alkylarginine motif)

SEQ ID No 8: GG*CRGDMFG*CGGLLSRHFRIGSRHSRIG

SEQ ID No 9: GG*CRGDMFG*CGGLLSIHFRIGSRHSRIG

SEQ ID No 10: GG*CRGDMFG*CGGLLFRHFRIGSRHSRIG.

5. (Original) The peptide as claimed in claim 1, characterized in that it contains a sequence

SEQ ID No 11: X-R-G-D-M-F-G-X'

exposing the RGD motif via a lactam bridge between the amino acids X (X)-C-O-NH-(X'), X and X' being amino acids such that one bears an acid group and the other bears an amine.

6. (Original) The peptide as claimed in claim 5, characterized in that it corresponds to the sequences SEQ ID No 12 to SEQ ID No 23:

SEQ ID No 12: GGXRGDMFGX'GGLLFIHFRIGCRHSRIG

SEQ ID No 13: GGXRGDMFGX'GGLLFIFFRIGCRFSRIG

SEQ ID No 14: GGXRGDMFGX'GGLLFIHFRIGSRHSRIG

SEQ ID No 15: GGXRGDMFGX'GGLLRIHFRIGSRHSRIG

SEQ ID No 16: GGXRGDMFGX'GG-LFIHFRIGSRHSRIG

SEQ ID No 17: GGXRGDMFGX'GGSLFIHFRIGSRHSRIG

SEQ ID No 18: GGXRGDMFGX'GGLLFIHFKIGSRHSRIG

SEQ ID No 19: GGXRGDMFGX'GGLLFIHF^NRIGSRHSRIG

(^NR representing an N-alkylarginine motif)

SEQ ID No 20: GGXRGDMFGX'GGLLSRHFRIGSRHSRIG

SEQ ID No 21: GGXRGDMFGX'GGLLSIHFRIGSRHSRIG

SEQ ID No 22: GGXRGDMFGX'GGLLFRHFRIGSRHSRIG

SEQ ID No 23: GGXRGDMFGX'GGLLFIHFRIGSRHSRIG

7. (Currently Amended) The peptide as claimed in claim 1 ~~any one of claims 1 to 6~~, characterized in that it induces apoptosis in human endothelial cells expressing $\alpha V\beta 3$ receptors.

8. (Currently Amended) The peptide as claimed in claim 1 ~~any one of claims 1 to 7~~, characterized in that it undergoes endocytosis by human endothelial cells expressing

$\alpha V\beta 3$ receptors, localizes in the mitochondrial compartment, and exerts a mitochondriotoxic effect.

9. (Currently Amended) A pharmaceutical composition, characterized in that it contains a therapeutically effective amount of at least one peptide as defined in claim 1 ~~any one of claims 1 to 8~~, in combination with a pharmaceutically acceptable vehicle.

10. (Original) The pharmaceutical composition as claimed in claim 9, characterized in that it is in the pharmaceutical form suitable for its administration by injection, in particular in the form of an injectable solution for intravenous administration.

11. (Currently Amended) The use of peptides as claimed in claim 1 ~~any one of claims 1 to 8~~, for producing antiangiogenic medicaments for the treatment of pathologies due to hypervascularization.

12. (Original) The use as claimed in claim 11, for producing medicaments for the treatment of solid tumors such as pulmonary tumors, adenomas, melanomas, prostate cancer, breast cancer, colon cancer, pancreatic cancer or osteosarcomas, or the treatment of diabetic retinopathies and of arthritis.